Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Heart Lung. 2015 May 13;44(4):276–281. doi: 10.1016/j.hrtlng.2015.03.006

Table 2. Negative Affectivity, Social Inhibition, Medication Adherence§, and Self-efficacy (N = 84).

Variable Unadjusted Adjusted
β 95% CI p β 95% CI p
Model 1 (without medication SE)
Negative Affectivity -.240 -.865 - -.013 .044* -.255 -.906 - -.025 .039***
Social Inhibition# -.057 -.506 - .306 .625 -.057 -.418 - .388 .940

Model 2 (with medication SE)
Negative Affectivity -.093 -.583 - .244 .417** -.122 -.651 - .204 .300****
Social Inhibition# .001 -.374 - .378 .991 .039 -.308 - .443 .722
Medication SE -.434 -.112 - -.038 < .001 -.405 -.107 - -.033 < .001

CI = confidence interval; SE = self-efficacy;

§

Outcome: medication adherence as measured by the Morisky Medication Adherence Scale-4

Negative affectivity was coded as 1; non- negative affectivity was coded as 2

#

Social Inhibition was coded as 1; non- negative affectivity was coded as 2

*

F = 3.160, p = .048

**

F = 7.882, p < .001

***

F = 2.384, p = .036. Adjusting for age, gender, left ventricular ejection fraction, and comorbidity

****

F = 4.387, p < .001. Adjusting for age, gender, left ventricular ejection fraction, and comorbidity